Is there a role for cannabidiol in psychiatry?

References

• Allsop DJ, Copeland J, Lintzeris N, Dunlop AJ, Montebello M, Sadler C, Rivas GR, Holland RM, Muhleisen P, Norberg MM, et al. 2014. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. JAMA Psychiatry. 71:281–291.
   PubMed Web of Science ®Google Scholar
• Ashton CH, Moore PB. 2011. Endocannabinoid system dysfunction in mood and related disorders. Acta Psychiatr Scand. 124:250–261.
   PubMed Web of Science ®Google Scholar
• Ashton CH, Moore PB, Gallagher P, Young AH. 2005. Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential. J Psychopharmacol. 19:293–300.
   PubMed Web of Science ®Google Scholar
• Bae JS, Kim JY, Park BL, Kim JH, Kim B, Park CS, Kim BJ, Lee CS, Lee M, Choi WH, et al. 2014. Genetic association analysis of CNR1 and CNR2 polymorphisms with schizophrenia in a Korean population. Psychiatr Genet. 24:225–229.
   PubMed Web of Science ®Google Scholar
• Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ, WFSBP Task Force on Treatment Guidelines for Anxiety Obsessive-Compulsive Post-Traumatic Stress Disorders. 2008. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry. 9:248–312.
   PubMed Web of Science ®Google Scholar
• Bergamaschi MM, Queiroz RH, Chagas MH, de Oliveira DC, De Martinis BS, Kapczinski F, Quevedo J, Roesler R, Schroder N, Nardi AE, et al. 2011a. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology. 36:1219–1226.
   PubMed Web of Science ®Google Scholar
• Bergamaschi MM, Queiroz RH, Zuardi AW, Crippa JA. 2011b. Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf. 6:237–249.
   PubMedGoogle Scholar
• Bhattacharyya S, Crippa JA, Martin-Santos R, Winton-Brown T, Fusar-Poli P. 2009. Imaging the neural effects of cannabinoids: current status and future opportunities for psychopharmacology. Curr Pharm Des. 15:2603–2614.
   PubMed Web of Science ®Google Scholar
• Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, Nosarti C, C M, O C, Seal M, Allen P, et al. 2010. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology. 35:764–774.
   PubMed Web of Science ®Google Scholar
• Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Moriello AS, Davis JB, Mechoulam R, Di Marzo V. 2001. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol. 134:845–852.
   PubMed Web of Science ®Google Scholar
• Bitencourt RM, Pamplona FA, Takahashi RN. 2008. Facilitation of contextual fear memory extinction and anti-anxiogenic effects of AM404 and cannabidiol in conditioned rats. Eur Neuropsychopharmacol. 18:849–859.
   PubMed Web of Science ®Google Scholar
• Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. 2015. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics. 12:825–836.
   PubMed Web of Science ®Google Scholar
• Boers M. 2010. Updated Consolidated Standards of Reporting Trials (CONSORT): it just gets better. J Clin Epidemiol. 63:813–814.
   PubMed Web of Science ®Google Scholar
• Bornheim LM, Everhart ET, Li J, Correia MA. 1994. Induction and genetic regulation of mouse hepatic cytochrome P450 by cannabidiol. Biochem Pharmacol. 48:161–171.
   PubMed Web of Science ®Google Scholar
• Breuer A, Haj CG, Fogaca MV, Gomes FV, Silva NR, Pedrazzi JF, Del Bel EA, Hallak JC, Crippa JA, Zuardi AW, et al. 2016. Fluorinated cannabidiol derivatives: enhancement of activity in mice models predictive of anxiolytic, antidepressant and antipsychotic effects. PloS One. 11:e0158779.
   PubMed Web of Science ®Google Scholar
• Campos AC, Ferreira FR, Guimaraes FS. 2012. Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5HT1A receptors. J Psychiatr Res. 46:1501–1510.
   PubMed Web of Science ®Google Scholar
• Campos AC, Fogaca MV, Sonego AB, Guimaraes FS. 2016. Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacol Res. 112:119–127.
   PubMed Web of Science ®Google Scholar
• Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimaraes FS. 2012. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci. 367:3364–3378.
   PubMed Web of Science ®Google Scholar
• Conselho Federal de Medicina. 2014. RESOLUÇÃO CFM N° 2.113/2014 - Aprova o uso compassivo do canabidiol para o tratamento de epilepsias da criança e do adolescente refratárias aos tratamentos convencionais. In: Brasília.
   Google Scholar
• Crippa JA, Derenusson GN, Ferrari TB, Wichert-Ana L, Duran FL, Martin-Santos R, Simoes MV, Bhattacharyya S, Fusar-Poli P, Atakan Z, et al. 2011. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol. 25:121–130.
   PubMed Web of Science ®Google Scholar
• Crippa JA, Hallak JE, Machado-de-Sousa JP, Queiroz RH, Bergamaschi M, Chagas MH, Zuardi AW. 2013. Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report. J Clin Pharm Ther. 38:162–164.
   PubMed Web of Science ®Google Scholar
• Crippa JA, Zuardi AW, Garrido GE, Wichert-Ana L, Guarnieri R, Ferrari L, Azevedo-Marques PM, Hallak JE, McGuire PK, Filho Busatto G. 2004. Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology. 29:417–426.
   PubMed Web of Science ®Google Scholar
• Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, Miller I, Flamini R, Wilfong A, Filloux F, et al. 2016. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 15:270–278.
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Piscitelli F. 2015. The endocannabinoid system and its modulation by phytocannabinoids. Neurotherapeutics. 12:692–698.
   PubMed Web of Science ®Google Scholar
• Eggan SM, Hashimoto T, Lewis DA. 2008. Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch Gen Psychiatry. 65:772–784.
   PubMed Web of Science ®Google Scholar
• Englund A, Morrison PD, Nottage J, Hague D, Kane F, Bonaccorso S, Stone JM, Reichenberg A, Brenneisen R, Holt D, et al. 2013. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol. 27:19–27.
   PubMed Web of Science ®Google Scholar
• Fusar-Poli P, Crippa JA, Bhattacharyya S, Borgwardt SJ, Allen P, Martin-Santos R, Seal M, Surguladze SA, O'Carrol C, Atakan Z, et al. 2009. Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry. 66:95–105.
   PubMed Web of Science ®Google Scholar
• Gardner EL. 2005. Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacol Biochem Behav. 81:263–284.
   PubMed Web of Science ®Google Scholar
• Gomes FV, Casarotto PC, Resstel LB, Guimaraes FS. 2011. Facilitation of CB1 receptor-mediated neurotransmission decreases marble burying behavior in mice. Prog Neuropsychopharmacol Biol Psychiatry. 35:434–438.
   PubMed Web of Science ®Google Scholar
• Gomes FV, Issy AC, Ferreira FR, Viveros MP, Del Bel EA, Guimaraes FS. 2014. Cannabidiol attenuates sensorimotor gating disruption and molecular changes induced by chronic antagonism of NMDA receptors in mice. Int J Neuropsychopharmacol. 18(5):pyu041.
   PubMed Web of Science ®Google Scholar
• Gomes FV, Resstel LB, Guimaraes FS. 2011. The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors. Psychopharmacology (Berl). 213:465–473.
   PubMed Web of Science ®Google Scholar
• Guimaraes VM, Zuardi AW, Del Bel EA, Guimaraes FS. 2004. Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum. Life Sci. 75:633–638.
   PubMed Web of Science ®Google Scholar
• Gururajan A, Malone DT. 2016. Does cannabidiol have a role in the treatment of schizophrenia? Schizophr Res. 176:281–290.
   PubMed Web of Science ®Google Scholar
• GW Pharmaceuticals. 2016. GW Pharmaceuticals announces positive phase 3 pivotal study for Epidolex (cannabidiol). London. Available from: http://www.gwpharm.com/GWPharmaceuticalsAnnouncesPositivPhase3PivotalStudyResultsforEpidiolexcannabidiol.aspx .
   Google Scholar
• Hallak JE, Dursun SM, Bosi DC, de Macedo LR, Machado-de-Sousa JP, Abrao J, Crippa JA, McGuire P, Krystal JH, Baker GB, et al. 2011. The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects. Prog Neuropsychopharmacol Biol Psychiatry. 35:198–202.
   PubMed Web of Science ®Google Scholar
• Heifets BD, Castillo PE. 2009. Endocannabinoid signaling and long-term synaptic plasticity. Annu Rev Physiol. 71:283–306.
   PubMed Web of Science ®Google Scholar
• Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, et al. 2015. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Int Med. 162:777–784.
   PubMed Web of Science ®Google Scholar
• Karniol IG, Shirakawa I, Kasinski N, Pfeferman A, Carlini EA. 1974. Cannabidiol interferes with the effects of delta 9 - tetrahydrocannabinol in man. Eur J Pharmacol. 28:172–177.
   PubMed Web of Science ®Google Scholar
• Khoury JM, Roque MAV, Queiroz DAB, Moreira FA, Garcia FD. 2016. Canabidiol em psiquiatria. In: PROPSIQ Programa de Atualização em Psiquiatria: Ciclo 5 Porto Alegre: Artmed Panamericana. p. 9–63.
   Google Scholar
• Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM. 2015. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol. 172:4790–4805.
   PubMed Web of Science ®Google Scholar
• Leweke M. 2013. The endocannabinoid system in schizophrenia - a mechanistically new approach to its pathophysiology and treatment. Schizophr Bull. 39(S1):S341.
   Google Scholar
• Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D. 1999. Elevated endogenous cannabinoids in schizophrenia. Neuroreport. 10:1665–1669.
   PubMed Web of Science ®Google Scholar
• Leweke FM, Koethe D. 2008. Cannabis and psychiatric disorders: it is not only addiction. Addict Biol. 13:264–275.
   PubMed Web of Science ®Google Scholar
• Leweke FM, Mueller JK, Lange B, Rohleder C. 2016. Therapeutic Potential of Cannabinoids in Psychosis. Biol Psychiatry. 79:604–612.
   PubMed Web of Science ®Google Scholar
• Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkotter J, Hellmich M, Koethe D. 2012. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2:e94.
   PubMed Web of Science ®Google Scholar
• Ligresti A, De Petrocellis L, Di Marzo V. 2016. From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology. Physiol Rev. 96:1593–1659.
   PubMed Web of Science ®Google Scholar
• Linge R, Jimenez-Sanchez L, Campa L, Pilar-Cuellar F, Vidal R, Pazos A, Adell A, Diaz A. 2016. Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors. Neuropharmacology. 103:16–26.
   PubMed Web of Science ®Google Scholar
• Lu HC, Mackie K. 2016. An introduction to the endogenous cannabinoid system. Biol Psychiatry. 79:516–525.
   PubMed Web of Science ®Google Scholar
• Mechoulam R, Gaoni Y, Hashish IV. 1965. The isolation and structure of cannabinolic cannabidiolic and cannabigerolic acids. Tetrahedron. 21:1223–1229.
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Arvanitis L, Bauer D, Rein W. Meta-Trial Study G. 2004. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry. 161:975–984.
   PubMed Web of Science ®Google Scholar
• Micale V, Di Marzo V, Sulcova A, Wotjak CT, Drago F. 2013. Endocannabinoid system and mood disorders: priming a target for new therapies. Pharmacol Ther. 138:18–37.
   PubMed Web of Science ®Google Scholar
• Moreira FA, Guimaraes FS. 2005. Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. Eur J Pharmacol. 512:199–205.
   PubMed Web of Science ®Google Scholar
• Morgan CJ, Curran HV. 2008. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry. 192:306–307.
   PubMed Web of Science ®Google Scholar
• Morgan CJ, Das RK, Joye A, Curran HV, Kamboj SK. 2013. Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addict Behav. 38:2433–2436.
   PubMed Web of Science ®Google Scholar
• Morgan CJ, Gardener C, Schafer G, Swan S, Demarchi C, Freeman TP, Warrington P, Rupasinghe I, Ramoutar A, Tan N, et al. 2012. Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. Psychol Med. 42:391–400.
   PubMed Web of Science ®Google Scholar
• Pedrazzi JF, Issy AC, Gomes FV, Guimaraes FS, Del-Bel EA. 2015. Cannabidiol effects in the prepulse inhibition disruption induced by amphetamine. Psychopharmacology (Berl). 232:3057–3065.
   PubMed Web of Science ®Google Scholar
• Pertwee RG. 2005. Pharmacological actions of cannabinoids. In: Cannabinoids. Heidelberg: Springer Berlin. p. 1–51.
   Google Scholar
• Pertwee RG, Ross RA, Craib SJ, Thomas A. 2002. (-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. Eur J Pharmacol. 456:99–106.
   PubMed Web of Science ®Google Scholar
• Prud'homme M, Cata R, Jutras-Aswad D. 2015. Cannabidiol as an intervention for addictive behaviors: a systematic review of the evidence. Substance abuse: research and treatment. 9:33–38.
   Google Scholar
• Russo EB, Burnett A, Hall B, Parker KK. 2005. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res. 30:1037–1043.
   PubMed Web of Science ®Google Scholar
• Sagheddu C, Muntoni AL, Pistis M, Melis M. 2015. Endocannabinoid signaling in motivation, reward, and addiction: influences on mesocorticolimbic dopamine function. IntRev Neurobiol. 125:257–302.
   PubMed Web of Science ®Google Scholar
• Sartim AG, Guimaraes FS, Joca SR. 2016. Antidepressant-like effect of cannabidiol injection into the ventral medial prefrontal cortex-Possible involvement of 5-HT1A and CB1 receptors. Behav Brain Res. 303:218–227.
   PubMed Web of Science ®Google Scholar
• Schubart CD, Sommer IE, van Gastel WA, Goetgebuer RL, Kahn RS, Boks MP. 2011. Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr Res. 130:216–221.
   PubMed Web of Science ®Google Scholar
• Shannon S, Opila-Lehman J. 2015. Cannabidiol oil for decreasing addictive use of marijuana: a case report. Integr Med (Encinitas). 14:31–35.
   PubMedGoogle Scholar
• Trigo JM, Lagzdins D, Rehm J, Selby P, Gamaleddin I, Fischer B, Barnes AJ, Huestis MA, Le Foll B. 2016. Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings. Drug Alcohol Depend. 161:298–306.
   PubMed Web of Science ®Google Scholar
• Trigo JM, Soliman A, Staios G, Quilty L, Fischer B, George TP, Rehm J, Selby P, Barnes AJ, Huestis MA, et al. 2016. Sativex associated with behavioral-relapse prevention strategy as treatment for cannabis dependence. A case series. J Addict Med. 10:274–279.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. 2015. Warning letters and test results for cannabidiol-related producs. Available from http://www.fda.gov/NewsEvents/PublicHealthFocus/ucm435591.htm
   Google Scholar
• WHO. 2002. Handbook for clinical research practice (GCP). In: Geneva: Office of Publications, World Health Organization.
   Google Scholar
• Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S, et al. 2015. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 313:2456–2473.
   PubMed Web of Science ®Google Scholar
• Winton-Brown TT, Allen P, Bhattacharyya S, Borgwardt SJ, Fusar-Poli P, Crippa JA, Seal ML, Martin-Santos R, Ffytche D, Zuardi AW, et al. 2011. Modulation of auditory and visual processing by delta-9-tetrahydrocannabinol and cannabidiol: an FMRI study. Neuropsychopharmacology. 36:1340–1348.
   PubMed Web of Science ®Google Scholar
• Zanelati TV, Biojone C, Moreira FA, Guimaraes FS, Joca SR. 2010. Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br J Pharmacol. 159:122–128.
   PubMed Web of Science ®Google Scholar
• Zuardi A, Crippa J, Dursun S, Morais S, Vilela J, Sanches R, Hallak J. 2010. Cannabidiol was ineffective for manic episode of bipolar affective disorder. J Psychopharmacol. 24:135–137.
   PubMed Web of Science ®Google Scholar
• Zuardi AW, Cosme RA, Graeff FG, Guimaraes FS. 1993. Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol (Oxford). 7:82–88.
   PubMed Web of Science ®Google Scholar
• Zuardi AW, Hallak JE, Dursun SM, Morais SL, Sanches RF, Musty RE, Crippa JA. 2006. Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol (Oxford) 20:683–686.
   PubMed Web of Science ®Google Scholar
• Zuardi AW, Morais SL, Guimaraes FS, Mechoulam R. 1995. Antipsychotic effect of cannabidiol. J Clin Psychiatry. 56:485–486.
   PubMed Web of Science ®Google Scholar
• Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. 1982. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl). 76:245–250.
   PubMed Web of Science ®Google Scholar